Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.

Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F, Suppressa P, Zarrabeitia R, Dupuis-Girod S, Shovlin CL, VASCERN-HHT.

Open source

DOI: 10.1186/s13023-018-0982-4
Published: 2019-02-04
Container: Orphanet J Rare Dis
Publisher: Figshare
Open access: yes

Credibility signals

uncertain Score 61/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0. Presence improves reuse transparency, not research validity. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13023-018-0982-4,
  title = {Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.},
  author = {Buscarini E and  Botella LM and  Geisthoff U and  Kjeldsen AD and  Mager HJ and  Pagella F and  Suppressa P and  Zarrabeitia R and  Dupuis-Girod S and  Shovlin CL and  VASCERN-HHT.},
  year = {2019},
  journal = {Orphanet J Rare Dis},
  doi = {10.1186/s13023-018-0982-4},
  url = {https://doi.org/10.1186/s13023-018-0982-4}
}

RIS

TY  - JOUR
TI  - Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.
AU  - Buscarini E
AU  -  Botella LM
AU  -  Geisthoff U
AU  -  Kjeldsen AD
AU  -  Mager HJ
AU  -  Pagella F
AU  -  Suppressa P
AU  -  Zarrabeitia R
AU  -  Dupuis-Girod S
AU  -  Shovlin CL
AU  -  VASCERN-HHT.
PY  - 2019
JO  - Orphanet J Rare Dis
DO  - 10.1186/s13023-018-0982-4
UR  - https://doi.org/10.1186/s13023-018-0982-4
ER  -

APA

E, B., LM, B., U, G., AD, K., HJ, M., F, P., P, S., R, Z., S, D., CL, S., & VASCERN-HHT. (2019). Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.. Orphanet J Rare Dis. https://doi.org/10.1186/s13023-018-0982-4

Source records

europe-pmc · retrieved 2026-09-26T07:44:58.404Z
datacite · retrieved 2026-09-26T07:44:58.380Z
datacite · retrieved 2026-09-26T07:44:58.380Z
doaj · retrieved 2026-09-26T07:44:58.392Z